Research
Hormonal
Tirzepatide has demonstrated superior weight loss efficacy compared to previously approved medications.
Tirzepatide may be considered as a more effective pharmacotherapy option for weight loss in patients compared to existing medications.
StrongSupportsmedium confidence
There are several phase 3 clinical trials that have demonstrated superior weight loss efficacy compared with previously approved medications.
Why this rating
Based on the mention of phase 3 clinical trials, which indicate a high level of evidence.
Source
Tirzepatide for Weight Loss: Can Medical Therapy “Outweigh” Bariatric Surgery?
Joel Novograd et al. · Cardiology in Review · 2023
DOI 10.1097/crd.0000000000000515
reviewCited 10×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →